Leiomyosarcoma: Research Studies

1 Related Result(s)

  1. A Phase II Study of the PARP Inhibitor Olaparib in Combination With the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma

    This phase II trial studies olaparib and temozolomide in treating patients with uterine leiomyosarcoma (LMS) that has spread to other places in the body ...